40 results
CORRESP
ADCT
Adc Therapeutics SA
28 Apr 20
Correspondence with SEC
12:00am
granted pursuant to the plans are calculated on the same basis using the traditional Black-Scholes option pricing model.
In consultation … with the independent third-party valuation specialists referred to above, the Company applies a Black-Scholes option pricing model-based valuation methodology
6-K
EX-99.1
ADCT
Adc Therapeutics SA
9 May 23
Condensed Consolidated Interim Statement of Operations
6:06am
." Commonly accepted pricing models (Black-Scholes) have been used to calculate the fair values. The valuation of the senior secured term loan … , using the Black-Scholes option-pricing model. Key inputs for the valuation of the warrant obligations as of March 31, 2023 were as follows
6-K
EX-99.1
ADCT
Adc Therapeutics SA
8 Nov 22
Condensed Consolidated Interim Statement of Operations
7:06am
measured at fair value using a Black-Scholes pricing model and is subsequently remeasured to fair value at each reporting date. Changes in the fair … " and for the Deerfield warrants in note 16, "Deerfield warrants". Commonly accepted pricing models (Black-Scholes) have been used to calculate the fair values
6-K
EX-99.1
ADCT
Adc Therapeutics SA
7 Nov 23
Condensed Consolidated Interim Statement of Operations
7:13am
, "Senior secured term loan facility and warrants" and for the Deerfield warrants in note 15, "Deerfield warrants." Commonly accepted pricing models (Black … information.
The Company used an independent valuation firm to assist in calculating the fair value of the warrant obligations, using the Black-Scholes option
6-K
EX-99.1
ADCT
Adc Therapeutics SA
8 Aug 23
Condensed Consolidated Interim Statement of Operations
7:07am
, "Senior secured term loan facility and warrants" and for the Deerfield warrants in note 15, "Deerfield warrants." Commonly accepted pricing models (Black … )" for further information.
The Company used an independent valuation firm to assist in calculating the fair value of the warrant obligations, using the Black
CORRESP
hbqn8wh
9 Sep 19
Correspondence with SEC
12:00am
6-K
EX-99.1
abveb3
15 Aug 22
Current report (foreign)
5:17pm
6-K
EX-99.4
0slxx
5 May 23
Invitation to the Annual General Meeting
8:00am
6-K
EX-99.3
adhml1p yuqz
5 May 23
Invitation to the Annual General Meeting
8:00am
6-K
EX-99.4
scwlzx0kau3z zoygs
18 Mar 21
Current report (foreign)
4:16pm
6-K
EX-99.4
2xew3w3c
17 Mar 22
Current report (foreign)
4:06pm
6-K
kztrcvevk9lxl5kqe79
15 Aug 22
Current report (foreign)
5:17pm
10-Q
5dyt5q
6 May 24
Quarterly report
6:38am
6-K
EX-99.2
mbrexr7qoe9oglrd10kx
18 Mar 21
Current report (foreign)
4:16pm
8-K
EX-99.2
jkvp8 cx3p
6 May 24
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
6:29am
6-K
EX-99.2
jxxk5kilgm3yo56mrkq
17 Mar 22
Current report (foreign)
4:06pm
F-1/A
ps3ou897z
14 May 20
Registration statement (foreign) (amended)
6:08am
6-K
EX-99.3
ou6dt54nwpg3pixx1
18 Mar 21
Current report (foreign)
4:16pm
F-1
yim55h sa
24 Apr 20
Registration statement (foreign)
5:23pm
F-1/A
nl2qm860 vt9
11 May 20
Registration statement (foreign) (amended)
6:26am